Alvotech SA
ALVO
查看详细走势图
3.110USD
0.0000.00%
收盘 03/27, 16:00（美东）报价延迟15分钟
938.62M总市值
31.10市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
-11.90%
1月
-22.06%
6月
-62.98%
今年开始到现在
-39.38%
1年
-67.43%
查看详细走势图
TradingKey Alvotech SA股票评分
单位: USD 更新时间: 2026-03-27操作建议
Alvotech SA当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名128/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.25。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Alvotech SA评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Alvotech SA亮点
亮点风险
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
业绩高增长
公司营业收入稳步增长，连续3年增长530.64%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值31.10，处于3年历史高位
机构加仓
最新机构持股18.18M股，环比增加0.63%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值73.36K
活跃度增加
近期活跃度增加，过去20天平均换手率1.47
分析师目标
根据
6
位分析师
买入
评级
7.250
目标均价
+123.77%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Alvotech SA新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Alvotech SA简介
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
公司代码ALVO
公司Alvotech SA
CEOWessman (Robert)
网址https://www.alvotech.com/
相关品种
